Abstract:Fragment-based drug discovery (FBDD) and validation of small molecule binders using NMR spectroscopy is an established and widely used method in the early stages of drug discovery. Starting from a library of small compounds, ligand- or protein-observed NMR methods are employed to detect binders, typically weak, that become the starting points for structure–activity relationships (SAR) by NMR. Unlike the more frequently used ligand-observed 1D NMR techniques, protein-observed 2D 1 H- 15 N or 1 H- 13 C heteronuclear correlation (HSQC or HMQC) methods offer insights that include the mechanism of ligand engagement on the target and direct binding affinity measurements in addition to routine screening. We hereby present the development of a set of software tools within the MestReNova (Mnova) package for analyzing 2D NMR for FBDD and hit validation purposes. The package covers three main tasks: (1) unsupervised profiling of raw data to identify outlier data points to exclude in subsequent analyses; (2) batch processing of single-point spectra to identify and rank binders based on chemical shift perturbations or spectral peak intensity changes; and (3) batch processing of multiple titration series to derive binding affinities ( K D ) by tracing the changes in peak locations or measuring global spectral changes. Toward this end, we implemented and evaluated a set of algorithms for automated peak tracing, spectral binning, and variance analysis by PCA, and a new tool for spectral data intensity comparison using ECHOS. The accuracy and speed of the tools are demonstrated on 2D NMR binding data collected on ligands used in the development of potential inhibitors of the anti-apoptotic MCL-1 protein.

Perspectives on Applications of 19F-NMR in Fragment-Based Drug Discovery

Recent progress in fragment-based drug discovery facilitated by NMR spectroscopy

Process of Fragment-Based Lead Discovery—A Perspective from NMR

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Application of Fragment-Based Drug Discovery to Versatile Targets

19F NMR: a Valuable Tool for Studying Biological Events.

Perspectives on Nuclear Magnetic Resonance Spectroscopy in Drug Discovery Research

Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR

A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments

Structure-based drug design: NMR-based approach for ligand-protein interactions.

Recent progress on fragment-based drug design

Protocol to perform fragment screening using NMR spectroscopy

The precious fluorine on the ring: fluorine NMR for biological systems

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance

Applications of “linkers” in Fragment-Based Drug Design

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

19F NMR as a versatile tool to study membrane protein structure and dynamics

A Ligand-observed Mass Spectrometry Approach Integrated into the Fragment Based Lead Discovery Pipeline